OncoMethylome Sciences to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma
OncoMethylome's Technology is being used in Roche Clinical Trial Program with Avastin
This trial will compare the current standard-of-care therapy, which is concurrent chemoradiation and adjuvant temozolomide "TMZ" (Temodar, Schering-Plough), with the standard-of-care plus bevacizumab (Avastin, Roche). All patients will be randomized to TMZ and radiotherapy or TMZ, radiotherapy and bevacizumab. OncoMethylome Sciences will receive payments for performing MGMT testing, using their patented Methylation-Specific PCR (MSP) technology, on all patients enrolled in this trial.
Mr. Luc Segers, Senior Director Business Development at OncoMethylome commented, "We are very pleased that MGMT testing will be incorporated into this study, once again demonstrating the market interest in identifying biomarkers that will lead to more personalized healthcare."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.